Semaglutides 1015% average weight reduction is well-documented across multiple large-scale trials and represents an established benchmark for GLP-1-based weight loss therapy
The Exercise Gap Many people assume that the weight loss from GLP-1s is "enough" and don't prioritize exercise
Patients who exhaust FSA balances mid-year can continue PlexusDx treatment at the same monthly rate using personal funds or an alternative payment method without interrupting their therapy
(PubMed) Minovic I, Kieneker LM, Gansevoort RT, et al
If your genetic profile indicates high sensitivity to GLP-1 signaling loss, PlexusDx providers may recommend longer taper periods, higher baseline protein intake during transition, or consideration of combination therapy to maintain your results
Deletion analysis has revealed that the essential portion of the promoter is only about 150 base pairs long